Abstracts tagged "Vaccination"

Abstract Number: 0390 • ACR Convergence 2021
Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Kimberly Showalter¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare…
Abstract Number: 1607 • ACR Convergence 2021
The Impact of Health Literacy and Numeracy on COVID-19 Vaccine Hesitancy in SLE
Rebecca Sadun¹, Mithu Maheswaranathan¹, Megan Clowse², Kai Sun¹, Jennifer Rogers¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Amanda Eudy¹, ¹Duke University, Durham, NC, ²Duke University, Chapel Hill, NC, ³Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR has issued guidance recommending COVID-19 vaccine for all patients with rheumatic diseases. Vaccine hesitancy research prior to the COVID-19 pandemic has demonstrated…
Abstract Number: 0457 • ACR Convergence 2021
Immunosuppression Attenuates Antibody and Neutralization Titers in Patients with Chronic Inflammatory Disease Following SARS-CoV-2 Vaccination
Michael Paley¹, Parakkal Deepak², Wooseob Kim², Monica Yang³, Alex Carividi³, Emanuel Demissie³, Alia A. El-Qunni,², Alem Haile², Katherine Huang², Baylee Kinnett², Mariel Liebeskind², Zhouming Liu², Lily E. McMorrow², Diana Paez³, Niti Pawar³, Dana Perantie², Rebecca E. Schriefer², Shannon Sides², Mahima Thapa², Sewuese Akuse⁴, Samantha Burdess², Abbey Rose², Lynne Mitchell², Salim Chahin², Matthew Ciorba², Jonathan Graf⁵, Patricia Katz³, Mehrdad Matloubian³, Jane O'Halloran², Rachel Presti², Gregory Wu², Sean Whelan², William Buchser², Lianne Gensler⁶, Mary Nakamura⁷, Ali H Ellebedy² and Alfred Kim², ¹Washington University in St. Louis, Olivette, MO, ²Washington University School of Medicine, St. Louis, MO, ³University of California San Francisco, San Francisco, CA, ⁴Washington University School of Medicine, St Louis, MO, ⁵Ucsf, San Francisco, CA, ⁶Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁷UCSF/SFVAHCS, San Francisco, CA
Background/Purpose: Individuals with chronic inflammatory diseases (CID) are frequently treated with immunosuppressive medications that can increase their risk of severe COVID-19. While novel mRNA-based SARS-CoV-2…
Abstract Number: 1616 • ACR Convergence 2021
Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley
Sukesh Sukumaran¹, Reshma Patel² and Deepika Singh³, ¹Valley Children's Healthcare, Madera, CA, ²Valley Children's Hospital, Madera, CA, ³Valley Children Healthcare, Madera, CA
Background/Purpose: The U.S. FDA has expanded the emergency use authorization of the COVID-19 vaccine to include children >12 years of age. Gaining an understanding of…
Abstract Number: 0640 • ACR Convergence 2021
Implementation of Digital Prompt in Electronic Medical Records Improves Pneumonia Vaccination Rates in Patients Prescribed TNF-Inhibitors
Manjeet Bhamra¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α inhibitors (TNFi) predispose to bacterial infections including pneumonia. In turn, vaccination with pneumococcal 13 valent (PCV13) and pneumococcal 23 valent…
Abstract Number: 1843 • ACR Convergence 2021
Perceptions and Concerns Regarding COVID-19 Vaccination in Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Jessica Gordon¹, Kimberly Showalter¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Hopital Cochin - Paris University, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: Hesitancy about COVID-19 vaccination exists among patients with rheumatic and musculoskeletal diseases, but previous studies have not assessed this specifically in patients with systemic…
Abstract Number: 0649 • ACR Convergence 2021
Optimizing SARS-CoV-2 Vaccine Timing in Rituximab-Treated Patients with Autoimmune Rheumatic Diseases: A Quality Improvement Intervention
Daniel Magliulo¹, Stefanie Wade² and Vasileios Kyttaris³, ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³BIDMC, Boston, MA
Background/Purpose: Experience with rituximab (RTX) in autoimmune rheumatic disease (AIRD) has shown a clear association with hypogammaglobulinemia, serious infections, and impaired humoral response to certain…
Abstract Number: 0964 • ACR Convergence 2021
Rituximab Treatment Dramatically Reduces Neutralizing Humoral Response to mRNA SARS-COV-2 Vaccines in Patients with Autoimmune Diseases
Samuel Bitoun¹, Julien Henry², Christelle Vauloup Fellous³, Raphaele Seror⁴, Lina Mouna³, Candie Joly⁵, Delphine Desjardins⁵, Marie Bitu⁵, Roger Le Grand⁶, Anne-Marie Roque Afonso³ and Xavier Mariette⁷, ¹Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Paris, France, ²Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184 FHU CARE, Le Plessis Robinson, France, ³AP–HP, Hôpital Paul-Brousse, Department of Virology, University Paris Saclay, INSERM U1193,, Villejuif, France, ⁴Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, INSERM UMR 1184, FHU CARE FHU CARE, Le kremlin Bicetre, France, ⁵Paris-Saclay University, Inserm UMR 1184, FHU CARE, CEA, Le Kremlin Bicêtre, France, ⁶UMR1184, IDMIT Department, Université Paris-Saclay, Inserm, CEA, Fontenay Aux Roses, France, ⁷Université Paris- Saclay, Rheumatology, Paris, France
Background/Purpose: The global COVID-19 pandemic is starting to be controlled by massive vaccination. Some immunosuppressed patients have already paid a high price to the pandemic…
Abstract Number: 0983 • ACR Convergence 2021
Anti-S1 Antibodies After Vaccination with Anti SARS-CoV-2 mRNA Vaccines in Patients with Rheumatoid Arthritis Differ in Magnitude and Kinetics from Healthy Controls: Results from a Prospective, Observational Controlled Study
Andrea Rubbert-Roth¹, Nicolas Vuilleumier², Burkhard Ludewig³, Kristin Schmiedeberg⁴, Yella Rottlaender⁴, Ian Pirker⁵ and Johannes VonKempis⁶, ¹Kantonspital St Gallen, St.Gallen, Switzerland, ²Departement Diagnostique, University of Geneva, Switzerland, Geneva, Switzerland, ³Institute of Immunobiology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁴Division of Rheumatology, Cantonal Hospital St Gallen, St Gallen, Switzerland, ⁵Kantonsspital St. Gallen, St.Gallen, Switzerland, ⁶Division of Rheumatology and Immunology, St. Gallen, Switzerland
Background/Purpose: Long-term vaccine-induced immunity to SARS-CoV-2 is critical to combat the pandemic. Vaccination against anti SARS-CoV-2 is recommended in patients with rheumatic diseases, but limited…
Abstract Number: 1086 • ACR Convergence 2021
Lack of Effect of SARS-CoV-2 Vaccination on Cell Bound Complement Activation Products (CB-CAPs), Multianalyte Assay Panel (MAP) with Algorithm, and Inflammatory Biomarkers
Mark Rudolph, Anja Kammensheidt and Roberta Alexander, Exagen Inc., Vista, CA
Background/Purpose: SARS-CoV-2 infection can lead to severe inflammation including increased complement activation (Ma, Kulkarni 2021) and the production of several proinflammatory cytokines. The rapid deployment…
Abstract Number: 1420 • ACR Convergence 2021
Evaluation of SARS-CoV-2 Vaccine Response in a Multi-Racial/Ethnic Cohort of Patients with Systemic Lupus Erythematosus
Peter Izmirly¹, Mimi Kim², Marie Samanovic-Golden³, Ruth Fernandez Ruiz⁴, Sharon Ohana³, Alexis Engel⁵, Kristina Deonaraine¹, Mala Masson⁴, Xianhong Xie⁶, Amber Cornelius⁴, Ramin Herati⁴, Rebecca Haberman⁴, Jose Scher¹, Allison Guttmann³, Rebecca Blank⁷, Ben Plotz³, Mayce Haj-Ali⁴, Brittany Banbury³, Sara Stream⁸, Ghadeer Hasan³, Gary Ho³, Paula Rackoff⁷, Ashira Blazer³, H. Michael Belmont³, Amit Saxena³, Mark Mulligan⁴, Robert Clancy⁴ and Jill Buyon³, ¹New York University School of Medicine, New York, NY, ²Albert Einstein College of Medicine, Larchmont, NY, ³NYU School of Medicine, New York, NY, ⁴NYU Grossman School of Medicine, New York, NY, ⁵NYU Langone Health, New Yok, NY, ⁶Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, NY, ⁷New York University, New York, NY, ⁸NYU Langone Health, New York, NY
Background/Purpose: Since the Phase 3 clinical studies of all three COVID-19 vaccines excluded patients on immunosuppressants or immune-modifying drugs within 6 months of enrollment, data…
Abstract Number: 1421 • ACR Convergence 2021
Efficacy and Tolerance of Vaccination Against COVID-19 in Patients with Systemic Lupus Erythematosus: The International VACOLUP Study
Renaud Felten¹, Lou KAWKA², Maxime DUBOIS², Manuel Ugarte-Gil³, Yurilis Fuentes-Silva⁴, Matteo PIGA⁵ and Laurent Arnaud¹, ¹Department of Rheumatology, French National Reference Center for Autoimmune Diseases (CRMR RESO), Strasbourg, France, ²National Reference Center for Rare East South-West Autoimmune Systemic Diseases RESO, Strasbourg University Hospitals, Strasbourg, France, ³Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁴Division of Rheumatology, Complejo Hospitalario Universitario Ruiz y Páez, Universidad de Oriente, Ciudad Bolívar, Centro Nacional de Enfermedades Reumáticas, Ciudad Bolívar, Venezuela, ⁵Department of Medical Science and Public Health, University of Cagliari, Cagliary, Italy
Background/Purpose: Both efficacy and safety data regarding COVID vaccines in systemic lupus erythematosus (SLE) are lacking. We conducted the international Vaccination Against COvid in systemic…
Abstract Number: 1535 • ACR Convergence 2021
Low Incidence and Transient Elevation of Autoantibodies Post mRNA COVID-19 Vaccination
Rebecca Blank¹, Rebecca Haberman², Rochelle Castillo², marie Samanovic³, Parvathy Vasudevanpillai Girija⁴, Paula Rackoff¹, Gary Solomon⁵, Natalie Azar⁶, Pamela Rosenthal⁷, Peter Izmirly⁴, Jonathan Samuels⁸, Brian Golden⁹, Soumya Reddy⁷, Steven B. Abramson⁴, Mark Mulligan³ and Jose Scher⁴, ¹New York University, New York, NY, ²NYU Langone Health, New York, NY, ³NYU Grossman School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU Langone School of Medicine, Hartsdale, NY, ⁶NYU Langone, New York, NY, ⁷NYU School of Medicine, New York, NY, ⁸NYU Langone, Rye Brook, NY, ⁹NYU Langone Medical Center - NYU Hospital for Joint Diseases, New York, NY
Background/Purpose: Recent studies have shown high rates of autoantibody production in patients hospitalized with COVID-19, including antinuclear antibodies (ANA) and antibodies associated with antiphospholipid syndrome.…
Abstract Number: 1536 • ACR Convergence 2021
Acceptability of Vaccines Against COVID-19 and Other Preventable Infections Among Patients with Rheumatic Disease
Sara Tedeschi¹, Jack Ellrodt¹, Jacklyn Stratton¹, Leah Santacroce¹, Paulette Chandler¹, Ellen Gravallese² and Daniel Solomon³, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ³Brigham and Women's Hospital, Newton, MA
Background/Purpose: Vaccination against preventable infections is widely recommended for patients with systemic rheumatic disease. The COVID-19 pandemic has highlighted variability in attitudes toward vaccination, particularly…
Abstract Number: 1546 • ACR Convergence 2021
Immune Responses to COVID-19 Vaccines in Patients Using Immunosuppressive Medication for Inflammatory Arthritis – An Observational Study of 1500 Patients
Ingrid Jyssum¹, Anne Therese Tveter¹, Fridtjof Lund-Johansen², Ludvig Munthe², Sella Provan¹, Kristin Jørgensen³, Gunnveig Grødeland², Grete Kro², David Warren², Joseph Sexton¹, Tore Kvien¹, Siri Mjaaland⁴, Espen Haavardsholm¹, John Torgils Vaage², Silje Watterdal Syversen¹ and Guro Goll¹, ¹Diakonhjemmet Hospital, OSLO, Norway, ²Oslo University Hospital, Oslo, Norway, ³Akershus University Hospital, Lørenskog, Norway, ⁴Norwegian Institute of Public Health, Oslo, Norway
Background/Purpose: To assess the strength and duration of the immunological response to COVID-19 vaccines in patients treated with immunosuppressive medication for inflammatory arthritis.Methods: Adult patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].